Vivek Subbiah shared a post on LinkedIn:

“Sharing a story of meeting with a legend …

A goosebumps moment & an example of what an amazing place Gustave Roussy INSERM Prism Center is ?

After my keynote lecture at Gustave Roussey this phenomenal person walks up to me.. . “Dr. Subbiah – great talk etc ……. you mentioned BRAF as tissue agnostic target….” Wait for it …

“by the way – my name is Alain Eychene – I cloned the BRAF gene in 1980’s” – wow

Such a great honor to meet with the one and only Alain Eychene !!!”

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.
OncoDaily